SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* MAHAFFY PATRICK J (Last) (First) (Middle) 2525 28TH STREET SUITE 200 (Street) BOULDER CO 80301 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol PHARMION CORP [ PHRM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) CEO, President
	3. Date of Earliest Transaction (Month/Day/Year) 03/07/2008
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/07/2008		M		9,375	A	$72.49(1)	366,998	D
Common Stock	03/07/2008		F		2,914	D	(1)	364,084	D
Common Stock	03/07/2008		D		364,084	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$72.49	03/07/2008		M			9,375	(1)	(1)	Common Stock	9,375	(1)	0	D
Employee Stock Option (right to buy)	$1.6	03/07/2008		D			18,750	01/29/2002	01/29/2009	Common Stock	18,750	(3)	0	D
Employee Stock Option (right to buy)	$2.4	03/07/2008		D			62,500	12/23/2002	12/23/2009	Common Stock	62,500	(4)	0	D
Employee Stock Option (right to buy)	$13.67	03/07/2008		D			22,870	12/02/2004	12/02/2010	Common Stock	22,870	(5)	0	D
Employee Stock Option (right to buy)	$42.34	03/07/2008		D			55,000	(6)	12/01/2011	Common Stock	55,000	(6)	0	D
Employee Stock Option (right to buy)	$35.15	03/07/2008		D			31,250	(7)	02/15/2012	Common Stock	31,250	(7)	0	D
Employee Stock Option (right to buy)	$18.49	03/07/2008		D			41,737	(8)	12/06/2012	Common Stock	41,737	(8)	32,813	D
Employee Stock Option (right to buy)	$24.81	03/07/2008		D			39,062	(9)	12/06/2013	Common Stock	39,062	(9)	85,938	D
Employee Stock Option (right to buy)	$18.49	03/07/2008		D			32,813	(10)	12/06/2012	Common Stock	32,813	(10)	0	D
Employee Stock Option (right to buy)	$24.81	03/07/2008		D			85,938	(11)	12/06/2013	Common Stock	85,938	(11)	0	D

Explanation of Responses:

1. 9375 restricted stock units, granted on 12/06/2006, vested on 03/07/08. Pharmion Corporation withheld 2914 shares of Pharmion Corporation common stock to pay the Reporting Person's withholding taxes related to such vesting.

2. Disposed of pursuant to the Agreement and Plan of Merger, dated November 18, 2007, by and between Pharmion Corporation, Celgene Corporation and Cobalt Acquisition LLC in exchange for $25.00 and 0.8367 shares of common stock of Celgene Corporation having a market value of $47.49 on the effective date of the merger.

3. These options were cancelled in the merger in exchange for $269,289.54 and 9,012 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

4. These options were cancelled in the merger in exchange for $887,502.14 and 29,701 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the reporting person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

5. These options were cancelled in the merger in exchange for $272,576.11 and 9,120 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

6. The options are exercisable in accordance with their vesting schedule. Twenty-five percent of the shares vest on the first anniversary date of the grant and 1/48th monthly thereafter. These options were cancelled in the merger in exchange for $335,980.93 and 11,243 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

7. The options are exercisable in accordance with their vesting schedule. Twenty-five percent of the shares vest on the first anniversary date of the grant and 1/48th monthly thereafter. These options were cancelled in the merger in exchange for $236,500.56 and 7,910 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

8. The options are exercisable in accordance with their vesting schedule. Twenty-five percent of the shares vest on the first anniversary date of the grant and 1/48th monthly thereafter. These options were cancelled in the merger in exchange for $456,672.38 and 15,280 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

9. The options are exercisable in accordance with their vesting schedule. Twenty-five percent of the shares vest on the first anniversary date of the grant and 1/48th monthly thereafter. These options were cancelled in the merger in exchange for $377,325.76 and 12,628 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.

10. The options are exercisable in accordance with their vesting schedule. These options were assumed by Celgene Corporation in the merger and replaced with options to purchase 42,057 shares of Celgene common stock for $14.43 per share.

11. The options are exercisable in accordance with their vesting schedule. These options were assumed by Celgene Corporation in the merger and replaced with options to purchase 110,152 shares of Celgene common stock for $19.36 per share.

Remarks:

Mr. Mahaffy transferred 311,250 options to purchase shares of common stock and 159,138 shares of common stock to his former spouse pursuant to a divorce decree. Mr. Mahaffy no longer reports as beneficially owned any securities owned by his former spouse.

	/s/ Erle T. Mast, Attorney-in-Fact	03/12/2008
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.